These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New drugs 2015, part 2. Hussar DA Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291 [No Abstract] [Full Text] [Related]
6. Apremilast, albiglutide, and empagliflozin. Hussar DA; Yenner S J Am Pharm Assoc (2003); 2014; 54(5):562-6. PubMed ID: 25216888 [No Abstract] [Full Text] [Related]
7. 2015 new drug update. Hussar DA Consult Pharm; 2015 Apr; 30(4):192-208. PubMed ID: 25893698 [TBL] [Abstract][Full Text] [Related]
8. Drug updates and approvals: 2017 in review. Mospan G; Mospan C; Vance S; Bradshaw A; Meosky K; Bowles K Nurse Pract; 2017 Dec; 42(12):8-16. PubMed ID: 29176433 [TBL] [Abstract][Full Text] [Related]
9. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Blair HA; Deeks ED Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674 [TBL] [Abstract][Full Text] [Related]
10. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD. Stanbrook MB Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800 [No Abstract] [Full Text] [Related]
11. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate. Hussar DA; Dharsi N J Am Pharm Assoc (2003); 2014; 54(4):450-2, 454-5. PubMed ID: 25063267 [No Abstract] [Full Text] [Related]
12. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Kelly E Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949 [TBL] [Abstract][Full Text] [Related]
13. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. Donohue JF; Singh D; Munzu C; Kilbride S; Church A Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016 [TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. Ramadan WH; Al Masri S; Rizk J Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190 [TBL] [Abstract][Full Text] [Related]
15. Fluticasone-vilanterol combination approved for COPD. Traynor K Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036 [TBL] [Abstract][Full Text] [Related]
17. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Feldman GJ; Edin A Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659 [TBL] [Abstract][Full Text] [Related]
18. Drug updates and approvals: 2015 in review. Klibanov OM; Phan D; Ferguson K Nurse Pract; 2015 Dec; 40(12):34-43; quiz 43-4. PubMed ID: 26545091 [TBL] [Abstract][Full Text] [Related]
19. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796 [TBL] [Abstract][Full Text] [Related]